Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482963 | 1.00 | CPB2 (0.44) | CPB2GSRGABRR1SLC7A5RNPEP | |
| SCHEMBL5615751 | 0.85 | SLC1A2 (0.49) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5280980 | 0.82 | GSR (0.50) | CPB2GSRGABRR1SLC7A5RNPEP | |
| SCHEMBL7271506 | 0.82 | GSR (0.50) | CPB2GSRGABRR1SLC7A5RNPEP | |
| SCHEMBL28011992 | 0.81 | GSR (0.45) | CPB2GSRGABRR1SLC7A5RNPEP | |
| SCHEMBL20915027 | 0.79 | GSR (0.44) | CPB2GSRGABRR1RNPEPSLC1A3 | |
| SCHEMBL20915026 | 0.79 | GSR (0.44) | CPB2GSRGABRR1RNPEPSLC1A3 | |
| SCHEMBL8388344 | 0.79 | GSR (0.47) | CPB2GSRGABRR1SLC7A5RNPEP | |
| SCHEMBL8497383 | 0.78 | CPB2 (0.36) | CPB2GSRGABRR1RNPEPLTA4H | |
| SCHEMBL1373660 | 0.78 | GSR (0.34) | CPB2GSRGABRR1SLC7A5RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030083380-A1 | Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging | YU RUEY J (US) | 2003-05-01 | — | — | US | claimed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | claimed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | claimed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | claimed |
| US-8124388-B2 | Production of 3-hydroxypropionic acid using beta-alanine/pyruvate aminotransferase | NOVOZYMES A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| EP-1706457-B1 | PRODUCTION OF 3-HYDROXYPROPIONIC ACID USING BETA-ALANINE/PYRUVATE AMINOTRANSFERASE | NOVOZYMES AS (DK) | 2012-02-01 | — | — | EP | disclosed |
| US-8043841-B2 | Nucleic acid molecules encoding alanine 2,3-aminomutases | NOVOZYMES A/S (DK) | 2011-10-25 | — | — | US | disclosed |
| US-20110183382-A1 | METHODS AND COMPOSITIONS FOR PRODUCING CHEMICAL PRODUCTS FROM C. PHYTOFERMENTANS | QTEROS, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2011081658-A2 | METHODS AND COMPOSITIONS FOR PRODUCING CHEMICAL PRODUCTS FROM C. PHYTOFERMENTANTS | QTEROS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-2292749-A2 | Alanine 2, 3 aminomutases | Novozymes A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292750-A2 | Alanine 2, 3 aminomutases | Novozymes A/S (DK) | 2011-03-09 | — | — | EP | disclosed |
| US-20110045573-A1 | ALANINE 2, 3-AMINOMUTASE | NOVOZYMES A/S | 2011-02-24 | — | — | US | disclosed |
| US-5643961-A | TREATMENT OF SKIN WITH COSMETICS | TRISTRATA TECHNOLOGY, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5637615-A | ANTIAGING AGENT | TRISTRATA TECHNOLOGY, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5580563-A | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof | ROCKEFELLER UNIVERSITY, THE | 1996-12-03 | — | — | US | disclosed |
| EP-0413528-B1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | YU RUEY J (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0671162-A2 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5385938-A | application of mixtures containing hydroxyacetic acid(or its salts) to skin | IGI, INC. | 1995-01-31 | — | — | US | disclosed |
| WO-1993022343-A1 | MULTIPLE ANTIGEN PEPTIDE SYSTEM HAVING ADJUVANT PROPERTIES AND VACCINES PREPARED THEREFROM | THE ROCKFELLER UNIVERSITY (US) | 1993-11-11 | — | — | WO | disclosed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045573-A1 | ALANINE 2, 3-AMINOMUTASE | ALAD, AGXT, ABAT | CPB2 126/4885GSR 2630/4885GABRR1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.